Eutilex.Co.,Ltd (KOSDAQ:263050)

South Korea flag South Korea · Delayed Price · Currency is KRW
959.00
+221.00 (29.95%)
At close: Feb 6, 2026
-48.77%
Market Cap 35.32B
Revenue (ttm) 10.29B
Net Income (ttm) -23.92B
Shares Out 36.83M
EPS (ttm) -650.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,750,673
Average Volume 1,127,177
Open 704.00
Previous Close 738.00
Day's Range 690.00 - 959.00
52-Week Range 650.00 - 3,200.00
Beta 0.92
RSI 60.03
Earnings Date Mar 27, 2026

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 263050
Full Company Profile

Financial Performance

In 2025, Eutilex.Co.,Ltd's revenue was 10.29 billion, an increase of 8.06% compared to the previous year's 9.53 billion. Losses were -23.92 billion, -17.98% less than in 2024.

Financial Statements

News

There is no news available yet.